100 Participants Needed

Geriatric Assessment for Multiple Myeloma

CT
Overseen ByClinical Trials Referral Office
Age: 65+
Sex: Any
Trial Phase: Academic
Sponsor: Mayo Clinic
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial aims to determine how a comprehensive geriatric assessment and specific lab tests can predict chemotherapy side effects in individuals with multiple myeloma, a type of blood cancer. Researchers seek to understand if these assessments can help adjust treatments for better outcomes. Participants will complete surveys, undergo a blood test, and have their medical records reviewed. Individuals aged 65 or older with newly diagnosed multiple myeloma, or who have had only one prior treatment and are about to start a new treatment, might be suitable candidates. As an unphased trial, this study offers participants the opportunity to contribute to important research that could enhance treatment strategies for future patients.

Do I need to stop my current medications for the trial?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What prior data suggests that the comprehensive geriatric assessment is safe for evaluating older patients with multiple myeloma?

Research has shown that a comprehensive geriatric assessment (CGA) is generally safe for older adults. Studies have found that CGA can lead to better outcomes, such as fewer hospital readmissions and lower mortality rates, compared to regular care. Older patients who undergo a CGA typically experience positive results without harmful side effects. The assessment includes various tests and questions to evaluate overall health, and most people find these manageable. No reports indicate negative effects specifically caused by the assessment process.12345

Why are researchers excited about this trial?

Researchers are excited about this trial because it focuses on evaluating comprehensive geriatric assessment (cGA) and laboratory biomarkers in elderly patients with multiple myeloma. Unlike traditional treatments that primarily target the cancer itself, this approach aims to tailor care based on the overall health and specific needs of older patients, which could lead to more personalized and effective treatment plans. By incorporating surveys, blood samples, and electronic health record reviews, the trial seeks to uncover crucial insights into how aging impacts treatment outcomes, potentially revolutionizing the way we approach cancer care in the elderly.

What evidence suggests that the comprehensive geriatric assessment is effective for predicting chemotherapy side effects in older patients with multiple myeloma?

Research has shown that a thorough health check-up for older adults, known as a comprehensive geriatric assessment (CGA), can improve health outcomes. Studies have found that CGA is associated with less disability, a better quality of life, and fewer hospital visits. For older adults in the hospital, CGA increases the likelihood of survival after treatment. While CGA doesn't significantly lower the overall death rate, it has reduced death rates at six months for frail older patients in the hospital. These findings suggest that CGA could enhance the management of older patients' health, leading to better treatment experiences.36789

Who Is on the Research Team?

SK

Shaji K. Kumar, MD

Principal Investigator

Mayo Clinic in Rochester

Are You a Good Fit for This Trial?

Inclusion Criteria

Newly diagnosed or have received 1 prior line of treatment
Planned to start a new treatment for MM within 30 days
Transplant eligible or ineligible
See 4 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Baseline Assessment

Participants undergo a comprehensive geriatric assessment (cGA) and laboratory biomarker evaluation

1 week
1 visit (in-person)

Treatment Observation

Participants are observed for chemotherapy toxicity and treatment-related adverse events over the first 4 months

16 weeks
Visits at the end of each treatment cycle

Follow-up

Participants are monitored for safety and effectiveness after treatment

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Comprehensive Geriatric Assessment

How Is the Trial Designed?

1

Treatment groups

Experimental Treatment

Group I: Observational (Surveys, cGA, blood sample, EHR review)Experimental Treatment4 Interventions

Find a Clinic Near You

Who Is Running the Clinical Trial?

Mayo Clinic

Lead Sponsor

Trials
3,427
Recruited
3,221,000+

Citations

The effectiveness of comprehensive geriatric assessment ...

This study showed a significant improvement in cognitive function favoring the CGA group at three months but found no significant difference at ...

Effectiveness of comprehensive geriatric assessment in ...

CGA did not significantly reduce overall mortality in frail older inpatients compared to usual care but lowered mortality rates at the 6-month follow-up.

Effectiveness of comprehensive geriatric assessment adapted ...

Our results suggest that a primary care CGA may have no impact on health-related quality of life; this finding differs from that of the Cochrane ...

Home‐Based Comprehensive Geriatric Assessment for ...

The evidence of CGA among hospitalized older adults has demonstrated favorable outcomes, resulting in an increased likelihood of being alive ...

geriatric assessment across healthcare settings

The CGA-based model of care was also associated with lower functional disability, improved quality of life, and reduced hospitalizations, with greater benefits ...

Comprehensive geriatric assessment – a guide for the non ...

A systematic review of comprehensive geriatric assessment to improve outcomes for frail older people being rapidly discharged from acute hospital: 'interface ...

Comprehensive geriatric assessment for older adults ...

The results of this meta-analysis indicate that CGA significantly reduces readmission and mortality rates in older adults compared to standard care.

Health outcomes and implementation barriers and facilitators ...

The authors revealed that CGA was associated with mixed findings on hospitalisation rates, no difference in functional and survival outcomes, ...

Comprehensive geriatric assessment - UpToDate

A comprehensive geriatric assessment includes functional status, activities of daily living, gait speed, falls/imbalance, cognition, mood ...